微创手术与开腹手术治疗上皮性卵巢癌的疗效与安全性:系统综述与荟萃分析
日本妇科肿瘤学会卵巢癌委员会专家组系统检索多个数据库,纳入35项研究、29888例上皮性卵巢癌患者,比较微创手术与开腹手术。微创手术与开腹手术的总生存率相似,围手术期并发症率相当,但微创手术的淋巴结清扫率和多脏器切除率更低。作者认为微创手术是可行选择,但病例选择和手术方式存在潜在偏倚,需进一步验证研究。
要点
- 微创手术与开腹手术的总生存率相似,各治疗类型差异均无统计学意义。
- 微创手术的围手术期并发症率与开腹手术相当,所有治疗类型P≥0.05。
- 微创手术的淋巴结清扫率和多脏器切除率低于开腹手术,差异有统计学意义。
核心结论
- 与开腹手术相比,微创手术未对上皮性卵巢癌患者的生存和围手术期并发症产生负面影响。
- 微创手术是可行选择,但病例选择和手术方式存在潜在偏倚,需进一步验证研究。
研究设计与样本
- 日本妇科肿瘤学会卵巢癌委员会专家组进行的系统综述与荟萃分析。
- 检索PubMed/MEDLINE、Cochrane Database和Ichushi等数据库,检索日期为2023年11月11日,关键词包括「上皮性卵巢癌」「微创手术」「腹腔镜」和「机器人辅助」。
- 由两位作者独立评估比较微创手术与常规腹部手术治疗上皮性卵巢癌的文章。
- 主要结局为生存和围手术期不良事件。
- 筛选1114项研究后纳入35篇文章,包括早期上皮性卵巢癌初次分期手术(n=20)、晚期上皮性卵巢癌新辅助化疗后间歇性肿瘤细胞减灭术(NACT-IDS;n=10)和初次肿瘤细胞减灭术(PDS;n=5)。
主要发现
- 微创手术与腹部手术的总生存率相似:初次分期手术OR 1.02(95%CI 0.75-1.37);NACT-IDS OR 0.93(95%CI 0.25-3.44);PDS OR 0.66(95%CI 0.36-1.22),所有P>0.05。
- 微创手术的围手术期并发症率与腹部手术相当,术中及术后所有治疗类型P≥0.05。
- 早期上皮性卵巢癌淋巴结清扫率微创手术低于腹部手术:初次分期手术OR 0.49(95%CI 0.26-0.91)。
- 晚期上皮性卵巢癌多脏器切除率微创手术低于腹部手术:NACT-IDS OR 0.27(95%CI 0.16-0.44);PDS OR 0.27(95%CI 0.16-0.44),所有P<0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 病例选择和手术方式存在潜在偏倚。
- 需进一步验证研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the efficacy and safety of minimally invasive surgery (MIS) and conventional abdominal surgery for epithelial ovarian cancer (EOC), stratified by treatment type. METHODS: A systematic review and meta-analysis were conducted by an Expert Panel of the Japan Society of Gynecologic Oncology Ovarian Cancer Committee. Several academic databases, including PubMed/MEDLINE, Cochrane Database, and Ichushi were searched by the Japan Medical Library Association on November 11, 2023, using the keywords "epithelial ovarian cancer", "minimally invasive surgery", "laparoscopic", and "robot-assisted". Articles describing MIS treatment for EOC compared with conventional abdominal surgery were independently assessed by two authors. The primary outcomes were survival and perioperative adverse events. RESULTS: After screening 1114 studies, 35 articles were identified, including primary staging surgery (PSS) for early-stage EOC EOC (n = 20) and neoadjuvant chemotherapy following interval debulking surgery (NACT-IDS; n = 10) and upfront primary debulking surgery (PDS; n = 5) for advanced-stage EOC. These studies included 29,888 patients (7661 undergoing MIS and 22,227 undergoing abdominal surgery). Patients receiving MIS and abdominal surgery had similar overall survival (PSS: odds ratio [OR] 1.02, 95% confidence interval [CI] 0.75-1.37; NACT-IDS: OR 0.93, 95%CI 0.25-3.44 and PDS: OR 0.66, 95%CI 0.36-1.22, all P > 0.05). MIS showed perioperative complication rates comparable to those of abdominal surgery (intraoperative and postoperative, all treatment types P ≥ 0.05). However, the rate of lymph node dissection in early-stage EOC (PSS: OR 0.49, 95%CI0.26-0.91) and multivisceral resections in advanced-stage EOC (NACT-IDS: OR 0.27 95%CI 0.16-0.44 and PDS: OR 0.27, 95%CI 0.16-0.44) was lower in MIS than in abdominal surgery (all P < 0.05). CONCLUSION: MIS did not negatively impact the survival and perioperative complications of patients with EOC compared to abdominal surgery. While MIS is a viable option, varied case selection and surgical procedures suggest potential bias, requiring further validation studies.
引用
- Yokoi A, Machida H, Shimada M, et al. Efficacy and safety of minimally invasive surgery versus open laparotomy for epithelial ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol. 2024. PMID: 39142091. doi:10.1016/j.ygyno.2024.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。